Please enable JavaScript.  This webapp requires JavaScript to work at its best.

Professor Marcia Brose Webinar


From the Eisai DTC webinar, this presentation by Professor Marcia Brose focusses on the use of TKIs in the treatment of differentiated thyroid cancer.

Watch Professor Brose review the evidence base on initiation time and dose including the latest data for Lenvatinib on starting dose and quality of life.

Supporting documentation:

LENVIMA® 4 mg hard capsules  Summary of Product Characteristics
LENVIMA® 10 mg hard capsules Summary of Product Characteristics

UK-LENA-23-00196  Date of preparation September 2023